Table 1.
Ongoing trials of antibody drug conjugates in TNBC.
| Drug | Target | Anti-body | Drug combinated | Study phase | Clinicaltrial.gov |
|---|---|---|---|---|---|
| Datopotamab deruxtecan (Dato-DXd) | TROP2 | Datopotamab | Single agent | I | NCT03401385 |
| + Durvalumab | I | NCT03742102 (ARM7) | |||
| +AZD5305(oral PARPi) | I | NCT04644068 (Module5) | |||
| Sacituzumab govitecan (IMMU-132) | TROP2 | Sacituzumab | Single agent | III | NCT04595565a |
| Single agent | II | NCT04647916b,c | |||
| + Avelumab | II | NCT03971409 | |||
| +/− Pembrolizumab | II | NCT04468061 | |||
| + Talazoparib | II | NCT04039230 | |||
| + Atezolizumab | I/II | NCT03424005 | |||
| Ladiratuzumab vedotin (SGN-LV1a) | LIV1 | Ladiratuzumab | Single agent | I | NCT01969643(excluded part B and E) |
| + Pembrolizumab | I/II | NCT03310957 | |||
| + Atezolizumab | I/II | NCT03424005 | |||
| SKB264 | TROP2 | Single agent | I/II | NCT04152499 | |
| Patritumab Deruxtecan (U3-1402) | HER3 | Patritumab | Single agent | II | NCT04965766 |
| Trastuzumab Deruxtecan (T-DXd) | HER2 | Trastuzumab | Single agent | Ib | NCT04556773d |
| Single agent | III | NCT03734029d | |||
| + Pembrolizumab | I | NCT04042701d | |||
| + Chemo or immunoagentse | I | NCT04556773d | |||
| + Durvalumab | I | NCT03742102 (ARM6) | |||
| +AZD5305(oral PARPi) | I | NCT04644068 (Module4) | |||
| Zilovertamab Vedotin (MK-2140) (VLS-101) | ROR1 | Zilovertamab | Single agent | II | NCT04504916 |
| Enfortumab Vedotin | nectin-4 | Enfortumab | Single agent | II | NCT04225117 (Cohort 2) |
| SGN-CD228A | Melanotransferrin (CD228) | anti-CD228 | Single agent | I | NCT04042480c |
| ASN004 | 5T4 oncofetal antigen (trophoblast glycoprotein) | Anti-5T4 | Single agent | I | NCT04410224 |
| CX-2009 | CD166 | Anti-CD166 | Single agent | II | NCT04596150 (Arm B) |
| +/−CX-072(pacmilimab)(PDL1i) | II | NCT04596150 (Arm C) | |||
| FDA018-ADC | TROP2 | Anti-TROP2 | Single agent | I | NCT05174637 |
| OBT076 (MEN1309) | CD205 | Anti-CD205 | Single agent | I | NCT04064359c |
| MRG002 | HER2 | anti-HER2IgG1 | Single agent | II | NCT04742153d |
| NBE-002 | ROR1 | Anti-ROR1 | Single agent | I/II | NCT04441099 |
| MORAb-202 | Folate Receptor Alpha (FRα) | Anti-FRα | Single agent | I/II | NCT04300556 |
| MGC018 | B7-H3 | Anti-B7-H3 | +/− Anti-PD1 (MGA012) | II | NCT03729596 |
| CAB-ROR2-ADC (BA3021) | CAB | Anti-CAR- ROR2 | +/− Pembrolizumab | I/II | NCT03504488 |
| PTK7-ADC (PF-06647020) | PTK7 | Cofetuzumab | + Gedatolisib | I | NCT03243331 |
| Trastuzumab Duocarmazine (SYD985) | HER2 | Trastuzumab | + Paclitaxel | I | NCT04602117 |
aPost-neoadjuvant;
bbrain metastases;
cin HER2-negative;
dHER2-low;
eDurvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine.